Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving Average – What’s Next?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $13.75 and traded as low as $10.86. Enanta Pharmaceuticals shares last traded at $11.07, with a volume of 158,110 shares changing hands.

Analyst Ratings Changes

Several research analysts have recently commented on ENTA shares. Rodman & Renshaw started coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $20.29.

Enanta Pharmaceuticals Price Performance

The company has a market capitalization of $321.92 million, a price-to-earnings ratio of -4.27 and a beta of 0.97. The business has a fifty day moving average price of $13.51 and a 200 day moving average price of $13.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. The company had revenue of $17.16 million during the quarter, compared to analyst estimates of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. Research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -1.79 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its stake in shares of Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after acquiring an additional 54,396 shares during the period. ADAR1 Capital Management LLC lifted its stake in shares of Enanta Pharmaceuticals by 24.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 51,357 shares of the biotechnology company’s stock worth $649,000 after acquiring an additional 10,000 shares during the period. Quantinno Capital Management LP lifted its stake in shares of Enanta Pharmaceuticals by 4.9% in the 1st quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock worth $444,000 after acquiring an additional 1,627 shares during the period. Spruce Street Capital LP lifted its stake in shares of Enanta Pharmaceuticals by 139.3% in the 1st quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock worth $11,779,000 after acquiring an additional 542,911 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Enanta Pharmaceuticals by 3.6% in the 1st quarter. Renaissance Technologies LLC now owns 665,258 shares of the biotechnology company’s stock worth $8,402,000 after acquiring an additional 23,058 shares during the period. 94.99% of the stock is owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.